Mumps Virus Antibody, IgG, Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Determination of post-immunization immune response of individuals to mumps virus
Documentation of previous infection with mumps virus in an individual with no previous record of immunization to mumps virus
Enzyme Immunoassay (EIA)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Mumps IgG Screen, S
Soft ID: MUMPI
Soft ID: MUMPI
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 1 mL
Forms: If not ordering electronically, submit a General Request Form (Supply T239) with the specimen.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross reject
Mild OK; Gross reject
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Mumps virus, together with parainfluenza virus types 1-4, respiratory syncytial virus, and measles virus are classified in the family Paramyxoviridae. Mumps is an acute infection which causes the painful enlargement of the salivary glands in approximately 70% to 90% of children (4-15 years of age) who develop clinical disease.(2) In 5% to 20% postpubertal individuals, testicular pain (orchitis in males) and abdominal pain (oophoritis in females) can occur. Other complications include pancreatitis (<5% of cases) and central nervous system disease (meningitis/encephalitis) that occur rarely (about 1 in 6,000 cases of mumps). Widespread routine immunization of infants with attenuated mumps virus has changed the epidemiology of this virus infection. Since 1989, there has been a steady decline in reported mumps cases. However, a recent outbreak of mumps, in 2006 re-emphasized that this virus continues to persist in the population, and laboratory testing may be needed in clinically compatible situations.
The laboratory diagnosis of mumps, is typically accomplished by detection of antibody to mumps virus. However due to the limitations of serology (eg, inadequate sensitivity and specificity), additional laboratory testing including virus isolation or detection of viral nucleic acid by PCR in throat, saliva or urine specimens should be considered in clinically compatible situations.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Negative (reported as positive, equivocal, or negative)
Index value 0.00-0.89=negative
Positive: Presence of detectable IgG-class antibodies indicates response to immunization or infection with mumps virus at sometime in the past. Individuals testing positive are considered immune to mumps virus infection.
Negative: Absence of detectable IgG-class antibodies suggests lack of a specific immune response to immunization or no previous exposure to mumps virus infection.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Mumps virus shares antigenic relationships with other viruses of the paramyxovirus group; therefore, serologic cross-reactions are possible, but uncommon with this test procedure.(2)
IgG-class antibodies to mumps virus may be present in serum specimens from individuals who have received blood products within the past several months but have not been immunized or experienced past infection with this virus.
To evaluate the accuracy of the mumps IgG EIA assay, 500 prospective serum specimens were analyzed using SeraQuest assay and the results compared to those using our current testing method (Biomerieux Vidas, IgG). The SeraQuest mumps IgG EIA demonstrated an overall agreement of 97% with a sensitivity and specificity of 96.7% and 97% respectively.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Harmsen T, Jongerius MC, van der Zwan CW, et al: Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps. J Clin Microbiol 1992 Aug;30(8):2139-2144
2. Hodinka RL, Moshal KL: Childhood infections. In Essentials of Diagnostic Virology. Edited by GA Storch. Churchill Livingstone, New York, 2000, pp168-178
Method Description Describes how the test is performed and provides a method-specific reference
The SeraQuest mumps IgG test is an EIA test. Diluted samples are incubated in Mumps (Enders strain) antigen-coated wells. If present, mumps antibodies are immobilized in the wells. Wells are washed, removing excess sample. Goat anti-human IgG (labeled with alkaline phosphatase) conjugate is added and the wells are incubated. If IgG antibodies to mumps are present, the conjugate will be immobilized in the wells. Wells are washed, removing excess conjugate. Substrate (p-nitrophenyl phosphate) is added and wells are incubated. If the enzyme conjugate is present, the substrate is converted to a yellow end product which is read photometrically.(Package insert: Mumps IgG, SeraQuest, 1938 NE 148th Terrace, North Miami, FL 33181)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday; 9 a.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Same day/1 day
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|MUMPG||Mumps IgG Screen, S||6476-6|